

Datasheet: HCA176

Description:	HUMAN ANTI TRASTUZUMAB
Specificity:	TRASTUZUMAB
Other names:	HERCEPTIN®
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD16712_hIgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation

Purified IgG prepared by affinity chromatography on Protein A

Buffer Solution

Phosphate buffered saline.

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml.

Immunogen

Trastuzumab (Herceptin®)

RRID

AB_11152942

Specificity

Human anti Trastuzumab, clone AbD16712_hlgG1, is an anti-idiotypic antibody that specifically recognizes the humanized monoclonal antibody drug trastuzumab, also known as Herceptin®. Clone AbD16712_hlgG can be used to measure the levels of trastuzumab and biosimilar products using bioanalytical assays.

In the HRP-conjugated format clone AbD16712_hlgG1 is ideal for use as a detection antibody in

pharmacokinetic (PK) assays. It is a fully human antibody and therefore may also be used as a calibrator in immune response assays to measure the anti-drug-antibody (ADA) response in patient sera.

Trastuzumab is a drug used in the treatment of HER2 positive breast cancer and other HER2 overexpressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells

[View a summary of all anti-trastuzumab antibodies.](#)

ELISA	This product may be used as a detection reagent in a sandwich ELISA, when conjugated to HRP, together with HCA169 as the capture reagent. Protocol: PK bridging ELISA to measure free drug This antibody is fully human and can be used as a reference standard in an ADA assay. Protocol: ADA bridging ELISA
References	1. Kashiwagi, N. <i>et al.</i> (2017) Method for measuring anti-drug antibody US Patent Application US20170315118 2. Iwamoto, N. <i>et al.</i> (2018) Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. Anal Biochem. 540-541: 30-7.
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch.
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Herceptin® is a registered trademark of Genentech, Inc.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Negative Controls

[RECOMBINANT HUMAN IgG1 LAMBDA ALLOTYPIC G1m3 \(HCA049\)](#)

Recommended Useful Reagents

[HUMAN ANTI TRASTUZUMAB \(HCA177\)](#)

[MOUSE ANTI HUMAN IgG \(Fc\) CH2 DOMAIN:HRP \(MCA647P\)](#)

[HUMAN ANTI TRASTUZUMAB \(HCA166\)](#)

[HUMAN ANTI TRASTUZUMAB \(HCA169\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK003P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK004P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK005P\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK006P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI TRASTUZUMAB \(HCA167\)](#)

[HUMAN ANTI TRASTUZUMAB \(HCA168\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

'M352466:190403'

Printed on 21 Oct 2019

© 2019 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)